Hsp90 Inhibitors as New Leads To Target Parasitic Diarrheal Diseases
Open Access
- 1 July 2014
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (7) , 4138-4144
Abstract
Entamoeba histolytica and Giardia lamblia are anaerobic protozoan parasites that cause amebiasis and giardiasis, two of the most common diarrheal diseases worldwide. Current therapy relies on metronidazole, but resistance has been reported and the drug has significant adverse effects. Therefore, it is critical to search for effective, better-tolerated antiamebic and antigiardial drugs. We synthesized several examples of a recently reported class of Hsp90 inhibitors and evaluated these compounds as potential leads for antiparasitic chemotherapy. Several of these inhibitors showed strong in vitro activity against both E. histolytica and G. lamblia trophozoites. The inhibitors were rescreened to discriminate between amebicidal and giardicidal activity and general cytotoxicity toward a mammalian cell line. No mammalian cytotoxicity was found at >100 μM for 48 h for any of the inhibitors. To understand the mechanism of action, a competitive binding assay was performed using the fluorescent ATP analogue bis-ANS (4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid dipotassium salt) and recombinant E. histolytica Hsp90 preincubated in both the presence and absence of Hsp90 inhibitors. There was significant reduction in fluorescence compared to the level in the control, suggesting that E. histolytica Hsp90 is a selective target. The in vivo efficacy and safety of one Hsp90 inhibitor in a mouse model of amebic colitis and giardiasis was demonstrated by significant inhibition of parasite growth at a single oral dose of 5 mg/kg of body weight/day for 7 days and 10 mg/kg/day for 3 days. Considering the results for in vitro activity and in vivo efficacy, Hsp90 inhibitors represent a promising therapeutic option for amebiasis and giardiasis.Keywords
This publication has 62 references indexed in Scilit:
- A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant Giardia lambliaAntimicrobial Agents and Chemotherapy, 2013
- Chemo-informatic design of antibiotic geldenamycin analogs to target stress proteins HSP90 of pathogenic protozoan parasitesBioinformation, 2013
- A high-throughput drug screen for Entamoeba histolytica identifies a new lead and targetNature Medicine, 2012
- Post-transcriptional Repair of a Split Heat Shock Protein 90 Gene by mRNA trans-SplicingJournal of Biological Chemistry, 2011
- Heat Shock Protein 90 as a Drug Target against Protozoan InfectionsJournal of Biological Chemistry, 2010
- Discovery and development of heat shock protein 90 inhibitorsBioorganic & Medicinal Chemistry, 2009
- Molecular Chaperones in Pathogen Virulence: Emerging New Targets for TherapyCell Host & Microbe, 2008
- Systems Analysis of Chaperone Networks in the Malarial Parasite Plasmodium falciparumPLOS Computational Biology, 2007
- Use of RecombinantEntamoeba histolyticaCysteine Proteinase 1 To Identify a Potent Inhibitor of Amebic Invasion in a Human Colonic ModelEukaryotic Cell, 2007
- A new medium for the axenic cultivation of Entamoeba histolytica and other EntamoebaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1978